Abstract
Over the past decade, the treatment of chronic myelogenous leukemia (CML) has gone through significant advances. Once an invariably fatal disease without stem cell transplant, it has since become one of the most manageable hematologic malignancies with good long-term outcomes. However, patients are not cured and require life-long treatment, and unfortunately, some of these patients develop resistant disease that progresses despite our best treatments. As our understanding of CML continues to grow, the repertoire of drugs available for successful treatment also increases. The following review discusses the current and future therapies for CML.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
